A Prospective Analytical Assessment of Cardiac Failure and its Prognostication with 3C: Reactive Protein as a Marker of Severity
Authors/Creators
- 1. Assistant Professor, Department of Medicine, Government Medical College, Bettiah, Bihar, India
- 2. Assistant Professor, Department of Psychiatry, Government Medical College, Bettiah, Bihar, India
Description
Aim: To evaluate the cardiac failure and its prognostication with 3C: Reactive protein as a marker of severity. Material & Methods: The cross-sectional analytical study was conducted in the Department of Medicine, Government Medical College, Bettiah, Bihar, India. Chagas disease was confirmed by 3 serological tests: direct agglutination, immunofluorescence, and enzyme- linked immunoassay (ELISA) and patients with 2 or more positive assays were accepted as positive. Results: The multiple regression analysis found no correlation between age and status of Chagas disease progression. Multiple regression analysis relating Chagas phase to serum IL-6 concentrations (analyzing the variables of age, sex, diabetes mellitus, hypertension, heart failure, and dyslipidemia), confirmed the hypothesis that IL-6 values show a significant correlation to disease phase. Although the simple correlation analyses showed a positive correlation between IL-6 or CRP and LVMI, a negative correlation between IL-6 or CRP and the ejection fraction, as well as between IL-6 and BMI, the multiple regression analysis did not confirm these results. Conclusion: Elevated IL-6 concentrations were related to the phase of Chagas disease, indicating that once these patients have progressed beyond the acute phase, they experience a chronic inflammatory process, which becomes more severe with progression to Phase III status.
Abstract (English)
Aim: To evaluate the cardiac failure and its prognostication with 3C: Reactive protein as a marker of severity. Material & Methods: The cross-sectional analytical study was conducted in the Department of Medicine, Government Medical College, Bettiah, Bihar, India. Chagas disease was confirmed by 3 serological tests: direct agglutination, immunofluorescence, and enzyme- linked immunoassay (ELISA) and patients with 2 or more positive assays were accepted as positive. Results: The multiple regression analysis found no correlation between age and status of Chagas disease progression. Multiple regression analysis relating Chagas phase to serum IL-6 concentrations (analyzing the variables of age, sex, diabetes mellitus, hypertension, heart failure, and dyslipidemia), confirmed the hypothesis that IL-6 values show a significant correlation to disease phase. Although the simple correlation analyses showed a positive correlation between IL-6 or CRP and LVMI, a negative correlation between IL-6 or CRP and the ejection fraction, as well as between IL-6 and BMI, the multiple regression analysis did not confirm these results. Conclusion: Elevated IL-6 concentrations were related to the phase of Chagas disease, indicating that once these patients have progressed beyond the acute phase, they experience a chronic inflammatory process, which becomes more severe with progression to Phase III status.
Files
IJPCR,Vol14,Issue7,Article74.pdf
Files
(134.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:66b3c4846569a4979e1e9eb2e7321270
|
134.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-07-10
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue7,Article74.pdf
- Development Status
- Active
References
- 1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26. 2. Koyama K, Yoneyama K, Mitarai T, et al. Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease. Arch Med Sci 2015; 11: 505-12. 3. Mrowiecki W, Sagan A, Guzik B, et al. Inflammatory aortic abdominal aneurysm – immunophenotypic characterization of inflammatory infiltrate. Arch Med Sci 2014; 10: 1258-62. 4. Tiyerili V, Becher UM, Camara B, et al. Impact of peroxisome proliferatoractivated receptor gamma on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice. Arch Med Sci 2015; 11: 877-85. 5. Dibra A, Mehilli J, Schwaiger M et al. Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. Eur Heart J 2003; 24: 1128-33. 6. Bisoendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007; 195: e10-8. 7. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511. 8. Xie D, Hu D, Zhang Q, Sun Y, Li J, Zhang Y. Increased high-sensitivity Creactive protein, erythrocyte sedimentation rate and lactic acid in stroke patients with internal carotid artery occlusion. Arch Med Sci 2016; 12: 546-51. 9. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. 10. Werdan K. The activated immune system in congestive heart failure. From dropsy to the cytokine paradigm. J Intern Med 1998; 243:87 –92.11. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479 –86. 12. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am Cardiol 1997; 79:1128 –31. 13. Ridker PM, Rifai N. C-Reactive Protein and Cardiovascular Disease. 1st ed. St-Laurent, Canada: Medi Edition Inc; 2006. 14. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132–140. 15. Ridker PM. A test in context: highsensitivity C-reactive protein. J Am Coll Cardiol 2016; 67:712–723. 16. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889–2934. 17. Samsonov M, Lopatin J, Tiltz GP. The activated immune system the renin– angiotensin–aldosterone system in congestive heart failure. J Intern Med 1998; 243:93 –8. 18. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997; 79:1128 –31. 19. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-21. 20. Sheriff A, Schindler R, Vogt B, et al. Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction? J ClinApher 2015; 30: 15-21. 21. Cunha-Neto E, Kalil J. Autoimmunity in Chagas' heart disease. Sao Paulo Med J. 1995; 113:757-66. 22. 17. Rossi MA. Microvascular changes as a cause of chronic cardiom- yopathy in Chagas' disease. Am Heart J. 1990; 120:233-6 23. Gao W, Pereira MA. Interleukin-6 is required for parasite specific response and host resistance to Trypanosoma cruzi. Int J Parasi- tol. 2002; 32:167- 70. Truyens C, Angelo-Barrios A, Torrico F, Van Damme J, Here- mans H, Carlier Y. Interleukin-6 (IL-6) production in mice infec- ted with Trypanosoma cruzi: effect of its paradoxical increase by anti-IL-6 monoclonal antibody treatment on infection and acute- phase and humoral immune responses. Infect Immun. 1994;62: 692-6. 24. Saavedra E, Herrera M, Gao W, Uemura H, Pereira MA. The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, upregulates interleukin 6 secretion in normal hu- man intestinal microvascular endothelial cells and peripheral blood mononuclear cells. J Exp Med. 1999; 190:1825-36 25. Hays P. Evidence Basis for Pharmacogenetic Testing in Psychiatry. Journal of Medical Research and Health Sciences, 2022:5(3), 1838–1859.